ASCO 2021: Nivolumab Plus Chemotherapy or Ipilimumab Offers Improved Outcomes Over Chemotherapy Alone in Advanced Esophageal Cancer
The dual immunotherapy regimen is the first chemotherapy-free first-line treatment to show benefit in this setting
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.